idh inhibitors and the evolving aml treatment paradigm
Published 2 years ago • 123 plays • Length 0:54Download video MP4
Download video MP3
Similar videos
-
1:44
improving maintenance therapy in aml: exploring the role of idh inhibitors
-
1:23
decitabine, venetoclax, and idh inhibitor in idh-mutated aml
-
1:14
the impact of idh mutations in mds & evaluating the role of idh inhibitors
-
1:32
idh inhibitors for aml and mds
-
2:13
a success story: idh inhibitors for aml
-
11:10
targeting idh mutations in glioma: implications of new data
-
4:10
explore idh mutations
-
1:36
idh mutations in cancer
-
2:08
the impact of idh mutations on the outcomes of patients with aml & inhibitors under investigation
-
2:22
session highlights: idh inhibitors, salvage regimens, and other novel developments in aml
-
2:49
results from the phase iii echo trial of acalabrutinib plus br in mcl
-
2:50
idh inhibition in aml therapy
-
2:33
novel immunotherapies in aml and insights into the future of the treatment landscape
-
1:53
treatment strategies for patients with idh1/2-mutated aml ineligible for intensive chemotherapy
-
2:57
targeting idh mutations for the treatment of aml
-
2:29
epitope editing enables the use of novel immunotherapies for aml
-
3:08
venetoclax-idh inhibitor combination therapy for aml
-
0:59
idh inhibitors in aml
-
1:51
idh1/2 inhibitors for upfront aml therapy and transfusion independence
-
2:31
idh mutations in aml treated with venetoclax
-
1:48
idh1 inhibitor ivosidenib for the treatment of relapsed/ refractory aml